Critical appraisal of drug therapy for nausea and vomiting of pregnancy: II. Efficacy and safety of diclectin (doxylamine-B6).

Abstract

Nausea and vomiting of pregnancy is the most common condition in pregnancy and affects up to 80% of all pregnant women. There are a large number of pharmacological agents that are effective for the treatment of nausea and vomiting associated with conditions such as motion sickness and gastrointestinal conditions; however, their use in pregnancy is limited by the lack of sufficient data on their potential teratogenic effects. The efficacy of the delayed-release combination of doxylamine and pyridoxine (Bendectin, Diclectin) has been shown in several randomized, controlled trials. The present review aims to refute the unsubstantiated beliefs that Diclectin is unsafe when used in the treatment of nausea and vomiting of pregnancy.

• Authors: R Bishai, P Mazzotta, G Atanackovic, Z Levichek, M Pole, L A Magee, G Koren
• Journal: The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique (Can J Clin Pharmacol) Vol. 7 Issue 3 Pg. 138-43 ( 2000) ISSN: 1198-581X [Print] Canada
• PMID: 11044759 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antiemetics
• Doxylamine
• Pyridoxine

Topics

• Antiemetics (pharmacokinetics, therapeutic use)
• Doxylamine (pharmacokinetics, therapeutic use)
• Female
• Humans
• Nausea (drug therapy, etiology)
• Pregnancy
• Pregnancy Complications (drug therapy)
• Pyridoxine (therapeutic use)
• Randomized Controlled Trials as Topic
• Vitamin B 6 Deficiency (complications)